Yüklüyor......
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis
Objective. To evaluate effects of tofacitinib or adalimumab on patient-reported outcomes (PROs) in patients with moderate to severe RA and inadequate responses to MTX. Methods. In this 12-month, phase 3, randomized controlled trial (ORAL Standard), patients (n = 717) receiving background MTX were ra...
Kaydedildi:
| Yayımlandı: | Rheumatology (Oxford) |
|---|---|
| Asıl Yazarlar: | , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Oxford University Press
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4870388/ https://ncbi.nlm.nih.gov/pubmed/26929445 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/rheumatology/kev442 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|